| Extracellular matrix structure AD Theocharis, SS Skandalis, C Gialeli, NK Karamanos Advanced drug delivery reviews 97, 4-27, 2016 | 2671 | 2016 |
| Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting C Gialeli, AD Theocharis, NK Karamanos The FEBS journal 278 (1), 16-27, 2011 | 1964 | 2011 |
| Glycosaminoglycans: key players in cancer cell biology and treatment# N Afratis, C Gialeli, D Nikitovic, T Tsegenidis, E Karousou, AD Theocharis, ... FEBS Journal, 2012 | 641 | 2012 |
| Emerging aspects of nanotoxicology in health and disease: from agriculture and food sector to cancer therapeutics Z Piperigkou, K Karamanou, AB Engin, C Gialeli, AO Docea, DH Vynios, ... Food and Chemical Toxicology 91, 42-57, 2016 | 118 | 2016 |
| Cell–matrix interactions: focus on proteoglycan–proteinase interplay and pharmacological targeting in cancer AD Theocharis, C Gialeli, P Bouris, E Giannopoulou, SS Skandalis, ... The FEBS journal 281 (22), 5023-5042, 2014 | 115 | 2014 |
| Syndecans as modulators and potential pharmacological targets in cancer progression D Barbouri, N Afratis, C Gialeli, DH Vynios, AD Theocharis, ... Frontiers in oncology 4, 4, 2014 | 109 | 2014 |
| Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid PG Dedes, C Gialeli, AI Tsonis, I Kanakis, AD Theocharis, D Kletsas, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1820 (12), 1926-1939, 2012 | 88 | 2012 |
| Novel potential inhibitors of complement system and their roles in complement regulation and beyond C Gialeli, B Gungor, AM Blom Molecular immunology 102, 73-83, 2018 | 78 | 2018 |
| Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin‐like growth factor receptor in the expression of cell surface … AI Tsonis, N Afratis, C Gialeli, MI Ellina, Z Piperigkou, SS Skandalis, ... The FEBS journal 280 (10), 2248-2259, 2013 | 69 | 2013 |
| PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts C Gialeli, D Nikitovic, D Kletsas, A D. Theocharis, G N. Tzanakakis, ... Current pharmaceutical design 20 (17), 2843-2848, 2014 | 63 | 2014 |
| Imatinib as a key inhibitor of the platelet‐derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast … CJ Malavaki, AE Roussidis, C Gialeli, D Kletsas, T Tsegenidis, ... The FEBS journal 280 (10), 2477-2489, 2013 | 62 | 2013 |
| Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer SS Skandalis, C Gialeli, AD Theocharis, NK Karamanos Advances in cancer research 123, 277-317, 2014 | 51 | 2014 |
| Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer A Escudero-Esparza, M Bartoschek, C Gialeli, M Okroj, S Owen, ... Oncotarget 7 (47), 76920, 2016 | 50 | 2016 |
| Cartilage Oligomeric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling KS Papadakos, M Bartoschek, C Rodriguez, C Gialeli, SB Jin, U Lendahl, ... Matrix Biology 81, 107-121, 2019 | 49 | 2019 |
| 1.1 Extracellular matrix: a functional scaffold A Theocharis, C Gialeli, V Hascall, NK Karamanos Extracellular matrix: pathobiology and signaling, 3-20, 2012 | 46 | 2012 |
| Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies C Gialeli, D Kletsas, D Mavroudis, HP Kalofonos, GN Tzanakakis, ... Current medicinal chemistry 16 (29), 3797-3804, 2009 | 39 | 2009 |
| Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered P Zarogoulidis, C Gialeli, NK Karamanos Therapeutic delivery 3 (9), 1021-1023, 2012 | 37 | 2012 |
| Extracellular matrix: paving the way to the newest trends in atherosclerosis C Gialeli, A Shami, I Gonçalves Current opinion in lipidology 32 (5), 277-285, 2021 | 36 | 2021 |
| The role of oligodendrocytes in the molecular pathobiology and potential molecular treatment of cervical spondylotic myelopathy SK Karadimas, CH Gialeli, G Klironomos, GN Tzanakakis, ... Current medicinal chemistry 17 (11), 1048-1058, 2010 | 34 | 2010 |
| Synthesis and Εvaluation of Αnticancer Αctivity in Cells of Novel Stoichiometric Pegylated Fullerene-Doxorubicin Conjugates GE Magoulas, M Bantzi, D Messari, E Voulgari, C Gialeli, D Barbouri, ... Pharmaceutical research 32, 1676-1693, 2015 | 33 | 2015 |
Nikos KaramanosProfessor of Biochemistry, University of Patras, Department of Chemistry, GreeceAdresă de e-mail confirmată pe upatras.gr